{"id":15956,"date":"2025-12-24T11:06:45","date_gmt":"2025-12-24T05:36:45","guid":{"rendered":"https:\/\/www.torusdigital.com\/toruscope\/?p=15956"},"modified":"2025-12-24T11:39:03","modified_gmt":"2025-12-24T06:09:03","slug":"stocks-to-buy-today-december-24-2025","status":"publish","type":"post","link":"https:\/\/www.torusdigital.com\/toruscope\/news\/stocks-to-buy-today-december-24-2025\/","title":{"rendered":"Stocks to Buy Today: December 24, 2025"},"content":{"rendered":"

[vc_section el_id=”blog-inner-layout”][vc_row overlay_dotted=””][vc_column el_class=”blog_primary”][vc_row_inner][vc_column_inner][vc_column_text css=””]The Indian stock market<\/a> is expected to begin Wednesday\u2019s session with a mildly positive yet cautious bias, supported by steady global cues and resilient domestic fundamentals. With holiday-thinned volumes ahead of Christmas, volatility is likely to remain contained, encouraging consolidation rather than sharp directional moves. Broader risk sentiment remains stable, suggesting the market is in a pause phase rather than a distribution phase.<\/p>\n

From a technical perspective, the Nifty 50<\/a> continues to trade within a healthy rising channel, holding above key moving averages. Immediate support is placed near 26,100, while the 26,000 to 25,950 zone acts as a strong demand base. As long as the index sustains above 26,000 on a closing basis, the near-term outlook remains mildly bullish with a buy-on-dips approach. Bank Nifty<\/a>, meanwhile, is expected to remain range-bound, supported by PSU banks, while private lenders consolidate after recent outperformance.<\/p>\n

Against this backdrop, select healthcare stocks<\/a> stand out due to their relative strength, liquidity, and sector resilience. Here are two stocks to watch today.<\/p>\n

<\/span>Global Health Ltd (Medanta | NSE: MEDANTA)<\/strong><\/span><\/h2>\n

Global Health Ltd<\/a>, which operates the Medanta hospital network, remains a key player in India\u2019s healthcare services space. The stock is trading marginally lower in today\u2019s session, reflecting broader market consolidation rather than company-specific weakness. Healthcare services continue to benefit from structural demand drivers such as rising medical tourism, increasing insurance penetration, and steady growth in elective procedures.<\/p>\n

Medanta\u2019s strong brand recall, presence across multiple metros, and focus on high-acuity specialties provide earnings visibility over the medium to long term. While valuations remain on the higher side, the company\u2019s consistent revenue growth and scalable hospital model support its premium positioning within the sector. In a cautious market, defensive healthcare names like Global Health often attract investor interest due to relatively stable cash flows.<\/p>\n

<\/span>Key Details <\/strong><\/span><\/h3>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Particulars<\/strong><\/td>\nDetails<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Previous Close (as of Dec 23, 2025)<\/td>\n\u20b91,188.00<\/td>\n<\/tr>\n
Day Range<\/td>\n\u20b91,173.90 \u2013 \u20b91,188.50<\/td>\n<\/tr>\n
Market Cap<\/td>\n\u20b9316.70 billion<\/td>\n<\/tr>\n
Average Volume<\/td>\n242.15K<\/td>\n<\/tr>\n
P\/E Ratio<\/td>\n56.40<\/td>\n<\/tr>\n
Dividend Yield<\/td>\n0.04%<\/td>\n<\/tr>\n
52-Week Range<\/td>\n\u20b9996.45 \u2013 \u20b91,456.50<\/td>\n<\/tr>\n
Company Type<\/td>\nLargecap Stock<\/a><\/td>\n<\/tr>\n
Beta<\/td>\n0.47<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Why to watch today:<\/strong>
\nGlobal Health offers defensive exposure within a consolidating market. Investors may track the stock for stability and potential accumulation on dips, especially as healthcare spending trends remain favourable.<\/p>\n

<\/span>Mankind Pharma Ltd (NSE: MANKIND)<\/strong><\/span><\/h2>\n

Mankind Pharma<\/a> has been drawing market attention after registering multiple consecutive sessions of gains earlier this week, supported by rising derivatives open interest and improved short-term momentum. Despite being down on a one-year basis compared with the broader indices<\/a>, the stock has shown relative strength in recent sessions, outperforming the Nifty Pharma index<\/a>.<\/p>\n

The recent surge in futures and options activity indicates active positioning by traders, pointing to expectations of further near-term price movement. Technically, the stock is trading above its short-term moving averages, signalling positive momentum, though it remains below longer-term averages, suggesting ongoing consolidation in the broader trend.<\/p>\n

Fundamentally, Mankind Pharma remains a major player in the domestic formulations space, with strong brand equity in chronic and acute therapies. Its large-cap status, high liquidity, and active participation from institutional and derivative traders make it a suitable stock for both short-term trading and medium-term monitoring.<\/p>\n

<\/span>Key Details <\/strong><\/span><\/h3>\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Particulars<\/strong><\/td>\nDetails<\/strong><\/td>\n<\/tr>\n<\/thead>\n
Previous Close (as of Dec 23, 2025)<\/td>\n\u20b92,229.60<\/td>\n<\/tr>\n
Day Range<\/td>\n\u20b92,212.00 \u2013 \u20b92,247.30<\/td>\n<\/tr>\n
Market Cap<\/td>\n\u20b9911.73 billion<\/td>\n<\/tr>\n
Average Volume<\/td>\n553.72K<\/td>\n<\/tr>\n
P\/E Ratio<\/td>\n51.97<\/td>\n<\/tr>\n
Dividend Yield<\/td>\n0.05%<\/td>\n<\/tr>\n
52-Week Range<\/td>\n\u20b92,090.00 \u2013 \u20b92,998.40<\/td>\n<\/tr>\n
Company Type<\/td>\nLargecap<\/td>\n<\/tr>\n
Beta<\/td>\n0.69<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Why to watch today:<\/strong>
\nMankind Pharma\u2019s rising derivatives interest and short-term price strength make it an attractive candidate for traders. Investors may also track the stock for signs of sustained accumulation once delivery volumes improve.<\/p>\n

<\/span>Conclusion<\/strong><\/span><\/h2>\n

Stock recommendations do not guarantee returns. In a market characterised by low volumes and cautious optimism, focusing on fundamentally strong and liquid stocks can help manage risk. Healthcare names such as Global Health Ltd and Mankind Pharma Ltd offer a mix of defensive stability and trading opportunities, making them relevant picks for today\u2019s session.<\/p>\n

Before taking any position, investors should evaluate their risk tolerance, time horizon, and strategy. Combining technical indicators with fundamental analysis and disciplined risk management, including stop-loss levels, remains essential.<\/p>\n

Just starting your investing journey? Open a Demat Account with Torus Digital<\/a> and take your first step towards informed stock market participation today.[\/vc_column_text][vc_column_text css=””][\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_id=”share_rating”][vc_column_inner width=”1\/2″][vc_column_text css=””]<\/p>\n

Rate this article<\/h6>\n